Join Zoom Meeting
https://mc-meet.zoom.us/j/95869608121?pwd=NG9GaG5JWE44eGpSckdRWHFSNnVkUT09

Meeting ID: 958 6960 8121
Passcode: 636276

Neuro-Oncology
Ugur Sener, M.D.
"Role of IDH inhibitors in treatment of IDH-mutant glioma: Current level of evidence and future perspectives"

Learning objectives: 
Upon conclusion of this activity, participants will be able to:

• Recognize importance of IDH mutation in gliomas for tumor classification and treatment planning.
• Interpret clinical trials studying IDH inhibitors for treatment of IDH-mutant gliomas.
• Critique recently published results from practice-changing phase 3 Indigo clinical trial.
• Assess areas for future investigation for use of IDH inhibitors.

Dr. Sener does have the following relevant financial relationships to disclose: Grant/Research support: Research funding through UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS) and does intend to discuss the following off-label/investigative use of Pharmaceuticals or Instruments: Servier: Ivosidenib and Vorasidenib.

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.